Search our Innovation Portfolio

Ceryx is developing a novel implantable bioelectronics therapeutic device targeting Heart Failure (HF). The technology will arrest, or reverse, HF pathology using a novel technique of modulating heart functions in line with respiration thereby improving efficiency and performance.

The final device will resemble a standard pacemaker or cardiac resynchronization therapy (CRT) device and, as such, implantation could be performed under local anaesthetic with a short hospital stay. Such a routine, low-risk and inexpensive procedure opens the possibility of Ceryx's device being used extensively to treat even early stage HF.

The technology will offer an effective alternative to pharmacotherapies, which are limited, largely ineffective and expensive.

Invitron is developing a portable device that will perform rapid, accurate diagnostic tests using just a small finger prick of blood. The device is based on a next generation chemiluminescence technology that will deliver laboratory quality results at the point of care. In this project we are developing a test that measures the biomarker B-type natriuretic peptide, a blood protein which is elevated in patients with heart failure (HF) and which can provide a definitive diagnosis of HF. This will enable HF to be identified directly in GP practices, reducing the time to diagnosis from several days to just a few minutes. This will in turn facilitate earlier treatment where necessary and rapidly rule out patients without HF.